School of Medicine, Washington University, St. Louis, MO 63130, USA.
Medicina (Kaunas). 2019 Sep 26;55(10):646. doi: 10.3390/medicina55100646.
Chronic obstructive pulmonary disease (COPD) accounts for the largest proportion of respiratory deaths worldwide and was historically the leading indication for lung transplantation. The success of lung transplantation procedures is measured as survival benefit, calculated as survival with transplantation minus predicted survival without transplantation. In chronic obstructive pulmonary disease, it is difficult to show a clear and consistent survival benefit. Increasing knowledge of the risk factors, phenotypical heterogeneity, systemic manifestations, and their management helps improve our ability to select candidates and list those that will benefit the most from the procedure.
慢性阻塞性肺疾病(COPD)占全球呼吸死亡的最大比例,历史上是肺移植的主要适应证。肺移植手术的成功以生存获益来衡量,即移植后的生存减去无移植时的预测生存。在慢性阻塞性肺疾病中,很难显示出明确和一致的生存获益。增加对风险因素、表型异质性、全身表现及其管理的认识有助于提高我们选择候选者的能力,并列出那些最能从该手术中获益的患者。